Editas shows better gene editing using Cas9 alternative for sickle cell, thalassemia

Editas preclinical data suggest Cas12a better than Cas9 for edited cell therapy for sickle cell, thalassemia

Editas is using an alternative to Cas9 to develop a differentiated sickle cell and β thalassemia CRISPR gene therapy. Preclinical data presented Monday at ASH suggest that ex vivo gene editing could be more effective via Cas12a.

Editas

Read the full 373 word article

User Sign In